Sandoz drug price-fixing settlement has gained preliminary approval for $400 million, benefiting states involved.
Rhapsido FDA approval brings new hope for patients with innovative treatment options.
Novartis India acquisition focuses on therapy-aligned growth strategies in Tier 2-3 markets.